240 related articles for article (PubMed ID: 33767438)
1. BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.
He F; Wu Z; Liu C; Zhu Y; Zhou Y; Tian E; Rosin-Arbesfeld R; Yang D; Wang MW; Zhu D
Signal Transduct Target Ther; 2024 May; 9(1):139. PubMed ID: 38811552
[TBL] [Abstract][Full Text] [Related]
3. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
[TBL] [Abstract][Full Text] [Related]
4. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
[TBL] [Abstract][Full Text] [Related]
5. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
6. A cytoplasmic role of Wnt/β-catenin transcriptional cofactors Bcl9, Bcl9l, and Pygopus in tooth enamel formation.
Cantù C; Pagella P; Shajiei TD; Zimmerli D; Valenta T; Hausmann G; Basler K; Mitsiadis TA
Sci Signal; 2017 Feb; 10(465):. PubMed ID: 28174279
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T
Feng M; Jin JQ; Xia L; Xiao T; Mei S; Wang X; Huang X; Chen J; Liu M; Chen C; Rafi S; Zhu AX; Feng YX; Zhu D
Sci Adv; 2019 May; 5(5):eaau5240. PubMed ID: 31086813
[TBL] [Abstract][Full Text] [Related]
8. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
9. BCL9 regulates CD226 and CD96 checkpoints in CD8
Feng M; Wu Z; Zhou Y; Wei Z; Tian E; Mei S; Zhu Y; Liu C; He F; Li H; Xie C; Jin J; Dong J; Yang D; Yu K; Qian J; Lambrechts D; Wang MW; Zhu D
Signal Transduct Target Ther; 2021 Aug; 6(1):313. PubMed ID: 34417435
[TBL] [Abstract][Full Text] [Related]
10. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
[TBL] [Abstract][Full Text] [Related]
11. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
[TBL] [Abstract][Full Text] [Related]
12. Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity.
Zhu M; Zhao Q; Zhang W; Xu H; Zhang B; Zhang S; Duan Y; Liao C; Yang X; Chen Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111168. PubMed ID: 37939513
[TBL] [Abstract][Full Text] [Related]
13. miR-22 and miR-214 targeting BCL9L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer.
Sun R; Liu Z; Han L; Yang Y; Wu F; Jiang Q; Zhang H; Ma R; Miao J; He K; Wang X; Zhou D; Huang C
FASEB J; 2019 Apr; 33(4):5411-5424. PubMed ID: 30698996
[TBL] [Abstract][Full Text] [Related]
14. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
15. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer.
Yang M; Wei Z; Feng M; Zhu Y; Chen Y; Zhu D
Front Oncol; 2021; 11():603556. PubMed ID: 34026600
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico.
Katoh M; Katoh M
Int J Mol Med; 2003 Oct; 12(4):643-9. PubMed ID: 12964048
[TBL] [Abstract][Full Text] [Related]
19. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
20. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.
Deka J; Wiedemann N; Anderle P; Murphy-Seiler F; Bultinck J; Eyckerman S; Stehle JC; André S; Vilain N; Zilian O; Robine S; Delorenzi M; Basler K; Aguet M
Cancer Res; 2010 Aug; 70(16):6619-28. PubMed ID: 20682801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
